The therapeutic effect of capmatinib and its application fields

Capmatinib is a targeted therapy drug mainly used in patients with MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC). Its therapeutic effect mainly focuses on precise intervention of abnormal activation of MET kinase, thereby inhibiting the growth and spread of tumors.

The therapeutic effects of capmatinib mainly include:

1.TargetingMETkinase: Capmatinib, as a targeted therapy drug, blocks the abnormal signaling related to the MET exon 14 skipping mutation by inhibiting the activity of METkinase, thereby slowing or preventing the growth of tumors.

2.Improve the objective response rate: Clinical trial data show that capmatinib exhibits a significant objective response rate in patients with METexon14skipping mutationNSCLC, providing patients with an effective treatment option.

3.Prolonged survival: The application of capmatinib can significantly prolong the survival of patients with METexon14skipping mutationNSCLC, providing patients with a longer chance of survival.

4.Personalized treatment: The application of capmatinib provides more personalized and targeted treatment options for patients with non-small cell lung cancer, and provides precise treatment based on the patient's genetic characteristics.

Capmatinib is not currently available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.